Skip Navigation

Cardiovascular Research 2007 75(2):390-397; doi:10.1016/j.cardiores.2007.02.026
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Klein, T.
Right arrow Articles by Kömhoff, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Klein, T.
Right arrow Articles by Kömhoff, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2007, European Society of Cardiology

Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition

Thomas Kleina, Manfrid Eltzea, Thomas Grebea, Armin Hatzelmanna and Martin Kömhoffb,*

aDepartments of Biochemistry and Pharmacology, ALTANA Pharma AG, D-78467 Konstanz, Germany
bDepartment of Pediatrics, Philipps-University, Baldingerstr, D-35041 Marburg, Germany

* Corresponding author. Tel.: +49 6421 2862650; fax: +49 6421 2868956. martin.komhoff{at}web.de

Objective Celecoxib carries a smaller cardiovascular risk for myocardial infarction and hypertension than other cyclooxygenase-2 (COX-2)-selective non-steroidal anti-inflammatory drugs NSAIDs ("coxibs") and may ameliorate endothelial dysfunction. We aimed to determine which mechanism possibly accounts for the beneficial effect by investigating its vascular action in different in vitro preparations in comparison with other coxibs and reference phosphodiesterase-5 (PDE5) inhibitors.

Methods To uncover potential effects on coronary flow, the effects of celecoxib in comparison with other NSAIDs and the PDE5 inhibitors, sildenafil and zaprinast, were investigated in guinea-pig Langendorff heart. This was supported by studies for vasorelaxation, interaction with the NO/cGMP pathway, and measurement of cyclic nucleotide amounts released from rat aortic rings, and inhibition of human PDE5 as well as PDE4 activity.

Results Bolus injections of sildenafil, celecoxib, and zaprinast (at 100 nmol) into the Langendorff heart increased coronary flow by approximately 100, 65, and 25%, respectively, while rofecoxib, lumiracoxib, parecoxib, and diclofenac, except valdecoxib (>100 nmol), failed to increase coronary flow up to 300 nmol. In rat aorta, sildenafil, celecoxib and zaprinast caused endothelium-dependent relaxation with –log[EC50]M values of 8.90, 6.66 and 5.56, respectively; their rank order of potency corresponds to their coronary dilatory effect. Celecoxib-induced relaxation of aorta was attenuated by the nitric oxide (NO) synthase inhibitor NG-nitro-L-arginine methyl ester (L-NAME, 10–4 M) and by the guanylate cyclase inhibitor 1H-[1,2,4]oxadiazolo[4,3-{alpha}]quinoxalin-1-one (ODQ, 10–5 M). In aortic rings, celecoxib (3x10–5 M) caused a fivefold increase in the cGMP level and potentiated that induced by sodium nitroprusside (5x10–7 M). Celecoxib and valdecoxib inhibited human PDE5A1 with an IC50 of 1.6x10–5 and 1x10–4 M, respectively, whereas other coxibs were without inhibitory effect.

Conclusion Celecoxib caused coronary vasodilatation in guinea-pig hearts and relaxation of rat aorta and had a potentiating effect on the NO/cGMP signaling pathway in rat aorta through specific blockade of PDE5. These unexpected findings clearly support the notion that celecoxib possesses an as yet undisclosed molecule-specific property that possibly compensates a decrease of prostacyclin-dependent cAMP generation by concomitantly increasing cGMP levels resulting from inhibition of PDE5.

KEYWORDS Coronary flow; Celecoxib; NSAID; PDE5; cGMP


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
L. I. Brueggemann, A. R. Mackie, B. K. Mani, L. L. Cribbs, and K. L. Byron
Differential Effects of Selective Cyclooxygenase-2 Inhibitors on Vascular Smooth Muscle Ion Channels May Account for Differences in Cardiovascular Risk Profiles
Mol. Pharmacol., November 1, 2009; 76(5): 1053 - 1061.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. P. Kellogg, K. Converso, T. Wiggin, M. Stevens, and R. Pop-Busui
Effects of cyclooxygenase-2 gene inactivation on cardiac autonomic and left ventricular function in experimental diabetes
Am J Physiol Heart Circ Physiol, February 1, 2009; 296(2): H453 - H461.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
J. Feng, E. Lucchinetti, G. Fischer, M. Zhu, K. Zaugg, M. C. Schaub, and M. Zaugg
Cardiac remodelling hinders activation of cyclooxygenase-2, diminishing protection by delayed pharmacological preconditioning: role of HIF1{alpha} and CREB
Cardiovasc Res, April 1, 2008; 78(1): 98 - 107.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
A. Martorell, J. Blanco-Rivero, R. Aras-Lopez, A. Sagredo, G. Balfagon, and M. Ferrer
Orchidectomy increases the formation of prostanoids and modulates their role in the acetylcholine-induced relaxation in the rat aorta
Cardiovasc Res, February 1, 2008; 77(3): 590 - 599.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Lamas, C. J. Lowenstein, and T. Michel
Nitric oxide signaling comes of age: 20 years and thriving
Cardiovasc Res, July 15, 2007; 75(2): 207 - 209.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.